Technology, Market, and Team.
Technology: We have identified a unique Biomarker for Triple Negative Breast Cancer and intend to further develop our highly differentiated anti-breast cancer therapies. We believe these therapies will also be effective for all kinds of breast cancers. We are also developing Companion Diagnostics for the detection of Triple Negative Breast Cancer. We are currently focused on the R & D of our one lead small molecule that we have identified in-house. We hold 4 US patents and file one PCT for our technology.
Market: According to Mordor Intelligence, the global cancer therapy market was $137 billion in 2018 and is estimated to be valued at $220 billion in 2024, witnessing a CAGR of 8.37%. According to Global Market Insights, the breast cancer therapy market is projected to hit $30.6 billion by 2025 with a 10.2% CAGR.
Team: Exceptionally qualified team of Scientists, Clinicians, Management team and Advisors with collective experience of over 80 years